Theratechnologies Announces a Supply, Distribution and Licensing Agreement with Actelion
Theratechnologies Inc. has announced that they have entered into a supply, distribution and licensing agreement with Actelion Pharmaceuticals Canada Inc. providing Actelion with the exclusive commercialization rights to tesamorelin in Canada.
Under the terms of the agreement, Actelion will be responsible for all ongoing regulatory and future commercialization activities in connection with tesamorelin in Canada.
Theratechnologies will be responsible for the manufacture and supply of tesamorelin to Actelion, who will purchase tesamorelin at a predetermined transfer price.
“Actelion represents the ideal partner for Theratechnologies in Canada. With a sales force already in place and trained in the commercialization of specialty treatments, Actelion will be in a position to effectively market tesamorelin, once approved. We look forward to tapping into their sales and marketing expertise in the commercialization of therapies in specialty markets as well as their extensive knowledge of the Canadian reimbursement system,” said John-Michel T. Huss, President and Chief Executive Officer of Theratechnologies.
“Balancing innovation, medical need and commercial potential is crucial in our decision to support a given product and we are confident that Theratechnologies’ innovative treatment for HIV patients with lipodystrophy fits the bill,” stated Jacques Archambault, President of Actelion Pharmaceuticals Canada.
“Our agreement with Theratechnologies will allow us to leverage our existing infrastructure in Canada, providing Theratechnologies with an established platform for an innovative product to the benefit of patients,” added Mr. Archambault.
“As previously stated, entering into commercial partnerships in markets around the world to increase revenues from sales of tesamorelin is Theratechnologies’ number one priority. We have signed an agreement which is in the best interest of our shareholders and Canadian patients who may eventually benefit from our novel therapy,” concluded Mr. Huss.